Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group

  • By

  • Natalia Fernández-Díaz

  • María Mateos-González

  • Ana Pertejo-Fernández

  • Juan Diego Cacho-Lavín

  • María José Juan-Fita

  • Isabel Chirivella-González

  • Mikel Arruti-Ibarbia

  • Ovidio Fernández-Calvo

  • Natalia Fernández-Núñez

  • María José Méndez-Vidal

  • Martín Lázaro-Quintela

  • Aurea Molina-Díaz

  • Nieves Del Pozo-Alonso

  • Olatz Etxaniz-Ulazia

  • Silvia Margarita García-Acuña

  • Yoel Z. Betancor

  • Ainara Azueta-Etxebarria

  • Ana Calatrava-Fons

  • Helena Lombardía-Rodríguez

  • Lorena Alarcón-Molero

  • Leire Etxegarai-Ganboa

  • Abraham Antón-Cameselle

  • José Antonio Bello-Giz

  • Carlos Manuel Neira-De Paz

  • Teresa Cabaleiro

  • Teresa González-Serrano

  • José Antonio Ortiz-Rey

  • Felipe Sacristán-Lista

  • Silvia García-Rubín

  • Elisa Ortega

  • Cristina Carrato-Moñino

  • Santiago Aguín-Losada

  • Luis León-Mateos

  • Jorge García-González

  • Álvaro Pinto-Marín

  • Ignacio Duran

  • Rafael López-López

  • Urbano Anido-Herranz

  • Juan Ruiz-Bañobre

  • November 28, 2025

Share

  • 1

    Nivolumab was approved for advanced renal cell carcinoma (aRCC) patients previously treated with anti-angiogenic agents in 2015.

  • 2

    The study analyzed 222 aRCC patients treated with nivolumab in Spain from December 2015 to October 2021.

  • 3

    The primary efficacy endpoint of the study was overall survival (OS), with secondary endpoints including progression-free survival (PFS) and disease control rate (DCR).

  • 4

    The median age of patients was 65 years, with 90% having undergone prior nephrectomy and clear cell renal cell carcinoma being the predominant subtype.

  • 5

    Results indicated that nivolumab treatment in routine clinical practice may differ from controlled clinical trial outcomes.

Original Source(s)

Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group

  • by Natalia Fernández-Díaz, María Mateos-González, Ana Pertejo-Fernández, Juan Diego Cacho-Lavín, María José Juan-Fita, Isabel Chirivella-González, Mikel Arruti-Ibarbia, Ovidio Fernández-Calvo, Natalia Fernández-Núñez, María José Méndez-Vidal, Martín Lázaro-Quintela, Aurea Molina-Díaz, Nieves Del Pozo-Alonso, Olatz Etxaniz-Ulazia, Silvia Margarita García-Acuña, Yoel Z. Betancor, Ainara Azueta-Etxebarria, Ana Calatrava-Fons, Helena Lombardía-Rodríguez, Lorena Alarcón-Molero, Leire Etxegarai-Ganboa, Abraham Antón-Cameselle, José Antonio Bello-Giz, Carlos Manuel Neira-De Paz, Teresa Cabaleiro, Teresa González-Serrano, José Antonio Ortiz-Rey, Felipe Sacristán-Lista, Silvia García-Rubín, Elisa Ortega, Cristina Carrato-Moñino, Santiago Aguín-Losada, Luis León-Mateos, Jorge García-González, Álvaro Pinto-Marín, Ignacio Duran, Rafael López-López, Urbano Anido-Herranz, Juan Ruiz-Bañobre

  • November 28, 2025

Related Content

Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling

Comment on “Life’s essential 8 and specific cancer risk and mortality in men and women: a population-based cohort analysis of 332,417 United Kingdom participants” and the inclusion of sleep in cancer focused guidelines

Intraoperative Evaluation of Sarcoma Surgical Margins With Indocyanine Green Fluorescence Imaging: Results From an Observational Study